335 related articles for article (PubMed ID: 18436554)
1. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.
Karageorgopoulos DE; Kelesidis T; Kelesidis I; Falagas ME
J Antimicrob Chemother; 2008 Jul; 62(1):45-55. PubMed ID: 18436554
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of tigecycline as a therapeutic option against multidrug-resistant Acinetobacter spp.
Eser OK; Ergin A; Tunçkanat F; Hasçelik G
New Microbiol; 2008 Oct; 31(4):535-42. PubMed ID: 19123310
[TBL] [Abstract][Full Text] [Related]
3. Emergence of tigecycline and colistin resistance in Acinetobacter species isolated from patients in Kuwait hospitals.
Al-Sweih NA; Al-Hubail MA; Rotimi VO
J Chemother; 2011 Feb; 23(1):13-6. PubMed ID: 21482488
[TBL] [Abstract][Full Text] [Related]
4. Bloodstream infections caused by Acinetobacter species with reduced susceptibility to tigecycline: clinical features and risk factors.
Park GE; Kang CI; Cha MK; Cho SY; Seok H; Lee JH; Kim JY; Ha YE; Chung DR; Peck KR; Lee NY; Song JH
Int J Infect Dis; 2017 Sep; 62():26-31. PubMed ID: 28676346
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy.
Guner R; Hasanoglu I; Keske S; Kalem AK; Tasyaran MA
Infection; 2011 Dec; 39(6):515-8. PubMed ID: 21789524
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
Park GC; Choi JA; Jang SJ; Jeong SH; Kim CM; Choi IS; Kang SH; Park G; Moon DS
Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259
[TBL] [Abstract][Full Text] [Related]
7. Tigecycline susceptibility in multidrug resistant Acinetobacter isolates from Turkey.
Yilmaz FF; Taşli H; Gül-Yurtsever S; Büyük A; Hoşgör-Limoncu M
Pol J Microbiol; 2013; 62(3):295-8. PubMed ID: 24459835
[TBL] [Abstract][Full Text] [Related]
8. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp.
Jones RN; Ferraro MJ; Reller LB; Schreckenberger PC; Swenson JM; Sader HS
J Clin Microbiol; 2007 Jan; 45(1):227-30. PubMed ID: 17093026
[TBL] [Abstract][Full Text] [Related]
9. Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009.
Morfin-Otero R; Dowzicky MJ
Clin Ther; 2012 Jan; 34(1):101-12. PubMed ID: 22177546
[TBL] [Abstract][Full Text] [Related]
10. [In vitro tigecycline and carbapenem susceptibilities of clinical Acinetobacter baumannii isolates].
Nayman Alpat S; Aybey AD; Akşit F; Ozgüneş I; Kiremitçi A; Usluer G
Mikrobiyol Bul; 2010 Oct; 44(4):641-5. PubMed ID: 21063976
[TBL] [Abstract][Full Text] [Related]
11. Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome.
Kim NH; Hwang JH; Song KH; Choe PG; Kim ES; Park SW; Kim HB; Kim NJ; Park WB; Oh MD
Scand J Infect Dis; 2013 Apr; 45(4):315-9. PubMed ID: 23113680
[TBL] [Abstract][Full Text] [Related]
12. Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline.
Curcio D; Fernández F; Vergara J; Vazquez W; Luna CM
J Chemother; 2009 Feb; 21(1):58-62. PubMed ID: 19297274
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections.
Metan G; Alp E; Yildiz O; Percin D; Aygen B; Sumerkan B
J Chemother; 2010 Apr; 22(2):110-4. PubMed ID: 20435570
[TBL] [Abstract][Full Text] [Related]
14. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii.
Navon-Venezia S; Leavitt A; Carmeli Y
J Antimicrob Chemother; 2007 Apr; 59(4):772-4. PubMed ID: 17353223
[TBL] [Abstract][Full Text] [Related]
15. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.
Schafer JJ; Goff DA; Stevenson KB; Mangino JE
Pharmacotherapy; 2007 Jul; 27(7):980-7. PubMed ID: 17594203
[TBL] [Abstract][Full Text] [Related]
16. Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective.
Curcio D; Fernández F
J Antimicrob Chemother; 2007 Aug; 60(2):449-50. PubMed ID: 17561503
[No Abstract] [Full Text] [Related]
17. Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review.
Poulikakos P; Tansarli GS; Falagas ME
Eur J Clin Microbiol Infect Dis; 2014 Oct; 33(10):1675-85. PubMed ID: 24832022
[TBL] [Abstract][Full Text] [Related]
18. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii clinical isolates.
Ricciardi R; Ricciardi AM; Danzi G
Infez Med; 2009 Dec; 17(4):236-9. PubMed ID: 20046104
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
Cai X; Yang Z; Dai J; Chen K; Zhang L; Ni W; Wei C; Cui J
Int J Antimicrob Agents; 2017 May; 49(5):609-616. PubMed ID: 28315729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
